Top

States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

After Capping Insulin Copays, Colorado Sets Its Sights on EpiPens

Almond, Soy Drinks Can Be Called Milk, FDA Proposes

GSK and Vir Biotech amend COVID-19 research partnership

Tag: Alkermes’ Lybalvi

FDA, Regulations

FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder

June 2, 2021

Via: Pharma Times

Lybalvi (olanzapine and samidorphan) has been authorised as maintenance monotherapy of adults with schizophrenia or bipolar I disorder, for the acute treatment of manic or mixed episodes and as monotherapy or an adjunct to lithium or valproate. In clinical trials, […]